PL366173A1 - 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists - Google Patents

4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists

Info

Publication number
PL366173A1
PL366173A1 PL01366173A PL36617301A PL366173A1 PL 366173 A1 PL366173 A1 PL 366173A1 PL 01366173 A PL01366173 A PL 01366173A PL 36617301 A PL36617301 A PL 36617301A PL 366173 A1 PL366173 A1 PL 366173A1
Authority
PL
Poland
Prior art keywords
neurokinin
phenyl
receptor antagonists
pyridine derivatives
pyridine
Prior art date
Application number
PL01366173A
Other languages
English (en)
Polish (pl)
Inventor
Torsten Hoffmann
Patrick Schnider
Heinz Stadler
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL366173A1 publication Critical patent/PL366173A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL01366173A 2000-07-24 2001-07-20 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists PL366173A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00115846 2000-07-24
PCT/EP2001/008432 WO2002008232A1 (en) 2000-07-24 2001-07-20 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists

Publications (1)

Publication Number Publication Date
PL366173A1 true PL366173A1 (en) 2005-01-24

Family

ID=8169331

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366173A PL366173A1 (en) 2000-07-24 2001-07-20 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists

Country Status (37)

Country Link
US (2) US6576762B2 (enExample)
EP (1) EP1305319B1 (enExample)
JP (1) JP4118673B2 (enExample)
KR (1) KR100527214B1 (enExample)
CN (1) CN1192032C (enExample)
AR (1) AR029875A1 (enExample)
AT (1) ATE322496T1 (enExample)
AU (2) AU8200501A (enExample)
BR (1) BR0112695A (enExample)
CA (1) CA2416874C (enExample)
CY (1) CY1106113T1 (enExample)
CZ (1) CZ2003528A3 (enExample)
DE (1) DE60118569T2 (enExample)
DK (1) DK1305319T3 (enExample)
EC (1) ECSP034446A (enExample)
ES (1) ES2260265T3 (enExample)
GT (1) GT200100148A (enExample)
HR (1) HRP20030031A2 (enExample)
HU (1) HU229231B1 (enExample)
IL (2) IL153837A0 (enExample)
JO (1) JO2321B1 (enExample)
MA (1) MA26933A1 (enExample)
MX (1) MXPA03000367A (enExample)
MY (1) MY129224A (enExample)
NO (1) NO20030353D0 (enExample)
NZ (1) NZ523452A (enExample)
PA (1) PA8522801A1 (enExample)
PE (1) PE20020258A1 (enExample)
PL (1) PL366173A1 (enExample)
PT (1) PT1305319E (enExample)
RU (1) RU2276139C2 (enExample)
SI (1) SI1305319T1 (enExample)
TW (1) TWI287003B (enExample)
UY (1) UY26851A1 (enExample)
WO (1) WO2002008232A1 (enExample)
YU (1) YU2803A (enExample)
ZA (1) ZA200300219B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103545B1 (en) * 1999-11-29 2003-11-05 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
DK1501808T3 (da) 2002-04-26 2008-10-13 Lilly Co Eli Tachykininreceptor-antagonister
EA007720B1 (ru) 2002-04-26 2006-12-29 Эли Лилли Энд Компани Производные триазола в качестве антагонистов рецептора тахикинина
AU2003300018A1 (en) * 2002-10-11 2004-05-04 Bristol-Myers Squibb Company Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents
US20060160794A1 (en) * 2003-06-12 2006-07-20 Amegadzie Albert K Tachykinin receptor antagonists
BRPI0412291A (pt) * 2003-07-03 2006-09-19 Hoffmann La Roche antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
US7288658B2 (en) * 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
DE602005026669D1 (de) 2004-07-06 2011-04-14 Hoffmann La Roche Herstellungsverfahren für carboxamid-pyridin-derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
US8067662B2 (en) 2009-04-01 2011-11-29 Aalnex, Inc. Systems and methods for wound protection and exudate management
US7816577B2 (en) 2006-02-13 2010-10-19 Aalnex, Inc. Wound shield
WO2007137954A1 (en) 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
PL3067349T3 (pl) 2013-11-08 2018-06-29 Kissei Pharmaceutical Co., Ltd. Pochodna karboksymetylopiperydyny
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
WO2016149324A1 (en) 2015-03-16 2016-09-22 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
CN115531553A (zh) * 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
ES2980110T3 (es) 2018-02-26 2024-09-30 Ospedale San Raffaele Srl Antagonistas de NK-1 para uso en el tratamiento del dolor ocular

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
SK283070B6 (sk) 1993-12-29 2003-02-04 Merck Sharp & Dohme Limited Substituované morfolínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
BR9908895A (pt) 1998-03-19 2000-12-05 Takeda Chemical Industries Ltd Composição farmacêutica, composto, pró-medicamento, composições para antagonizar um receptor, uso de um composto, e, processos para produzir um composto, para antagonizar um receptor, para evitar ou tratar distúrbios de micção em mamìferos e distúrbios de asma, artrite reumatóide, osteoartrite, dor, tosse, sìndrome do intestino irritável ou vÈmitos em mamìferos
PL350428A1 (en) * 1999-02-24 2002-12-16 Hoffmann La Roche 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
CN1131212C (zh) * 1999-02-24 2003-12-17 弗·哈夫曼-拉罗切有限公司 苯基－和吡啶基衍生物
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
EP1103545B1 (en) * 1999-11-29 2003-11-05 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
ATE400556T1 (de) * 2000-07-14 2008-07-15 Hoffmann La Roche N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten

Also Published As

Publication number Publication date
KR20030015898A (ko) 2003-02-25
US6576762B2 (en) 2003-06-10
CY1106113T1 (el) 2011-06-08
CA2416874A1 (en) 2002-01-31
US20020038030A1 (en) 2002-03-28
JP2004504400A (ja) 2004-02-12
HU229231B1 (en) 2013-09-30
WO2002008232A1 (en) 2002-01-31
DK1305319T3 (da) 2006-08-14
CN1192032C (zh) 2005-03-09
CZ2003528A3 (cs) 2003-09-17
AU8200501A (en) 2002-02-05
PE20020258A1 (es) 2002-04-02
ZA200300219B (en) 2004-04-08
BR0112695A (pt) 2003-04-22
HUP0301272A2 (hu) 2003-08-28
GT200100148A (es) 2002-05-16
PA8522801A1 (es) 2002-09-30
HRP20030031A2 (en) 2004-02-29
DE60118569D1 (de) 2006-05-18
UY26851A1 (es) 2002-01-31
MXPA03000367A (es) 2003-05-27
NO20030353L (no) 2003-01-23
MY129224A (en) 2007-03-30
NO20030353D0 (no) 2003-01-23
DE60118569T2 (de) 2007-02-15
PT1305319E (pt) 2006-08-31
AU2001282005B2 (en) 2006-10-19
KR100527214B1 (ko) 2005-11-08
YU2803A (sh) 2006-01-16
US6624176B2 (en) 2003-09-23
CA2416874C (en) 2011-01-18
ECSP034446A (es) 2003-03-10
EP1305319A1 (en) 2003-05-02
SI1305319T1 (sl) 2006-08-31
JO2321B1 (en) 2005-09-12
TWI287003B (en) 2007-09-21
HK1058360A1 (en) 2004-05-14
RU2276139C2 (ru) 2006-05-10
JP4118673B2 (ja) 2008-07-16
MA26933A1 (fr) 2004-12-20
EP1305319B1 (en) 2006-04-05
CN1444589A (zh) 2003-09-24
US20030130508A1 (en) 2003-07-10
IL153837A (en) 2008-06-05
IL153837A0 (en) 2003-07-31
AR029875A1 (es) 2003-07-16
ES2260265T3 (es) 2006-11-01
ATE322496T1 (de) 2006-04-15
NZ523452A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
AU1211802A (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
AU8200501A (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
IL153308A0 (en) Thrombin receptor antagonists
AU9384701A (en) Metabotropic glutamate receptor antagonists
ZA200408670B (en) Trizole derivatives as tachykinin receptor antagonists.
IL155999A0 (en) Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
AU4274401A (en) Diphenylalkylamine derivatives useful as opioid delta receptor agonists
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
EP1359915A4 (en) UROTENSIN-II RECEPTOR ANTAGONISTS
GB0028104D0 (en) Bombesin receptor antagonists
EP1351687A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
IL150272A0 (en) Indole derivatives as mcp-1 receptor antagonists
AU2002359524A8 (en) P2x7 receptor antagonists
GB0028146D0 (en) Bombesin receptor antagonists
IL158063A0 (en) Crf receptor antagonists
MXPA03005581A (es) Pirrolidinas substituidas como antagonistas del receptor ccr-3.
SI1294714T1 (sl) Antagonisti trobinskega receptorja
GB0107914D0 (en) 7tm receptor hlwar77

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)